Davis Aaron I.'s Form 4 filing
Tango Therapeutics, Inc. (TNGX) · filed Jul 2, 2024
- Accession no.
- 0000895345-24-000245
- Filed
- Jul 2, 2024, 8:56 PM ET
- Trade date
- Jun 28-Jul 2, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $2.06M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis Aaron I.CIK 0001465914 | Other: See remarks |
| MVA Investors, LLCCIK 0001468223 | Other: See remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 28, 2024 | Common Stock | SSaleDisposed | −29,000 | $8.57F1 | −$248,530 | 314,524 | Direct | |
| Jul 1, 2024 | Common Stock | SSaleDisposed | −110,731 | $8.87F3 | −$982,183.97 | 203,793 | Direct | |
| Jul 2, 2024 | Common Stock | SSaleDisposed | −95,000 | $8.68F4 | −$824,600 | 108,793 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.48 to $8.68, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.75 to $9.00, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $9.05, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
The reporting persons may be deemed members of a group that beneficially owns more than 10% of the outstanding shares of common stock, $0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. As to any reporting person that is not a beneficial owner of more than 10% of the outstanding shares of Common Stock, this Form 4 shall not be deemed a concession that such person is subject to Section 16 of the Securities Exchange Act of 1934 with respect to the issuer.